Concepedia

Author

Jianming Xu

Sun Yat-sen UniversityORCID

Also Known As

Felipe Reyes-Cosmelli, Guangyu An, J M Xu, J Xu, J. M. Xu, J. Xu, J.-M. Xu, J.M. Xu, JIANMING XU, Jian Ming Xu

383

Publications

26.5K

Citations

56

H-Index

70

Concepts

All Affiliations

Sun Yat-sen UniversityChinese PLA General HospitalHarbin Medical UniversityPeking UniversityPeking University Cancer Hospital
JX

About

Jianming Xu is an author at Sun Yat-sen University specializing in medicine, oncology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

26

48

13.8K

2

Health Sciences

13

13

7.8K

3

Gastroenterology

13

16

2.3K

4

Hepatology

4

4

7.3K

5

Cell Biology

3

3

121

Jianming Xu

×

127

Publications

25.5K

Citations

56

H-Index

YearCitations

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen,

The Lancet Oncology

2008

5.8K

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

George D. Demetri, Peter Reichardt, Yoon‐Koo Kang,

The Lancet

2012

1.4K

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Zhenggang Ren, Jianming Xu, Yuxian Bai,

The Lancet Oncology

2021

1K

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

Jin Li, Shukui Qin, Jianming Xu,

Journal of Clinical Oncology

2016

976

Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)

Jian Zhou, Hui‐Chuan Sun, Zheng Wang,

Liver Cancer

2020

813

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

Jin Li, Shukui Qin, Rui‐Hua Xu,

The Lancet Oncology

2015

791

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

Philip J. Johnson, Shukui Qin, Joong‐Won Park,

Journal of Clinical Oncology

2013

765

Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Deng‐Yn Lin,

Journal of Clinical Oncology

2013

762

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Yelena Y. Janjigian, Akihito Kawazoe, Patricio Yañez,

Nature

2021

648

Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study

Taroh Satoh, Rui‐Hua Xu, Hyun Cheol Chung,

Journal of Clinical Oncology

2014

611

Page 1